Clinical Trials Browser

INDUSTRY × Carcinoma, Non-Small-Cell Lung × brigatinib × Clear all

Carcinoma, Non-Small-Cell Lung

NCT05721950 2026-02-18

Brilliant

Active not recruiting

154 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05834348 2025-03-30

DELINOR

Completed

5,279 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03546894 2024-07-15

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Completed

111 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02706626 2023-01-26

Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

Phase 2 Terminated

32 enrolled 9 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02737501 2021-08-20

ALTA-1L

Phase 3 Completed

275 enrolled 23 charts 1 FDA

Thoracic

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

NCT01449461 2021-08-17

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)

Phase 1/2 Completed

137 enrolled 38 charts

LymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Large-Cell, Anaplastic

NCT02094573 2021-03-15

A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Phase 2 Completed

222 enrolled 23 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02784158 2018-02-06

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

No longer available

Thoracic

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

Clinical Trials

Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer

Brilliant

DELINOR

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

ALTA-1L

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)

A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer